Phosphoproteomic analysis of basal and therapy‐induced adaptive signaling networks in BRAF and NRAS mutant melanoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1615-9861|15|2-3|327-339

ISSN： 1615-9853

Source： PROTEOMICS, Vol.15, Iss.2-3, 2015-01, pp. : 327-339

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK

By  

PIGMENT CELL & MELANOMA RESEARCH, Vol. 28, Iss. 3, 2015-05 ,pp. : 307-317

John Wiley & Sons Inc

Access to resources Recommend Favorite

The broad‐spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF‐mutant melanoma cells in combination with other signaling pathway inhibitors

By  

PIGMENT CELL & MELANOMA RESEARCH, Vol. 28, Iss. 4, 2015-07 ,pp. : 417-430

John Wiley & Sons Inc

Access to resources Recommend Favorite

Quantitative phosphoproteomic analysis of IL‐33‐mediated signaling

By  

PROTEOMICS, Vol. 15, Iss. 2-3, 2015-01 ,pp. : 532-544

John Wiley & Sons Inc

Access to resources Recommend Favorite

Naevus lightening in melanoma patients under BRAF/MEK inhibitor combination therapy versus checkpoint immunotherapy: A histological and immunohistochemistry analysis

By  

PIGMENT CELL & MELANOMA RESEARCH, Vol. 31, Iss. 2, 2018-03 ,pp. : 341-344

John Wiley & Sons Inc

Access to resources Recommend Favorite

Detailed imaging and genetic analysis reveal a secondary BRAFL505H resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib

By  

PIGMENT CELL & MELANOMA RESEARCH, Vol. 28, Iss. 3, 2015-05 ,pp. : 318-323

John Wiley & Sons Inc

Access to resources Recommend Favorite